Trials that use: P-values
New to this method? Read the tutorial →
20,601 results
- Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer: Complete Statistical AnalysisIndependent statistical analysis of Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar: Complete Statistical AnalysisIndependent statistical analysis of Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00176202).
- RITA-2Independent statistical analysis of Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-2): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- RITAPSIndependent statistical analysis of A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Rituximab and ABVD for Hodgkin’s Patients: Complete Statistical AnalysisIndependent statistical analysis of Rituximab and ABVD for Hodgkin's Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00504504).
- Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder: Complete Statistical AnalysisIndependent statistical analysis of Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom’s Macroglobulinemia: Complete Statistical AnalysisIndependent statistical analysis of Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size…
- Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM): Complete Statistical AnalysisIndependent statistical analysis of Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH): Complete Statistical AnalysisIndependent statistical analysis of Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01086540).
- Rituximab in Pretreated Elderly or Unfit B-CLL Patients: Complete Statistical AnalysisIndependent statistical analysis of Rituximab in Pretreated Elderly or Unfit B-CLL Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01576588).
- Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Rituximab in Treating Patients With Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Rituximab in Treating Patients With Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00003820).
- Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Rituximab or Zevalin – Efficacy Trial of Therapeutic Alternatives (RoZetta): Complete Statistical AnalysisIndependent statistical analysis of Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01662102).
- Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue: Complete Statistical AnalysisIndependent statistical analysis of Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01611259).
- Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval,…
- Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells: Complete Statistical AnalysisIndependent statistical analysis of Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells: primary endpoint results, effect estimate with confidence…
- Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL: Complete Statistical AnalysisIndependent statistical analysis of Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- RIVALIndependent statistical analysis of A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- RIVER-PCIComplete statistical analysis of RIVER-PCI, a randomized phase 3 trial of ranolazine versus placebo after PCI in patients with coronary artery disease and angina pectoris, including time-to-event endpoints, Cox modeling, hazard ratios,…
- RJIndependent statistical analysis of RESOLUTE Japan - The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- RLICCIndependent statistical analysis of Effect of Number of Remote Limb Ischemic Conditioning Cycles on Learning Enhancement: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- RLP-MHIndependent statistical analysis of Reproductive Life Planning for Women With Mental Illness: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03969589).
- RLSIndependent statistical analysis of Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- RLS-PractiseIndependent statistical analysis of Non-interventional Study (NIS) in Patients With Restless Legs Syndrome in Daily Practise: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- RMCL-CL001Independent statistical analysis of Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- RMTMVAIndependent statistical analysis of Effects of Respiratory Muscle Training in Mechanically Ventilated Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02469064).
- RN-Led Palliative and Supportive Care Intervention: Complete Statistical AnalysisIndependent statistical analysis of RN-Led Palliative and Supportive Care Intervention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04570709).
- RN624 In Adult Patients With Chronic Low Back Pain: Complete Statistical AnalysisIndependent statistical analysis of RN624 In Adult Patients With Chronic Low Back Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00584870).
- RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- ROADACEIndependent statistical analysis of Reactions of Older Adults Driving After Cannabis Exposure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04629716).
- ROBOPHYSEIndependent statistical analysis of Da Vinci Transoral Robotic-assisted Surgery of Pituitary Gland: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02743442).
- Robotic and Conventional Hand Therapy After Stroke: Complete Statistical AnalysisIndependent statistical analysis of Robotic and Conventional Hand Therapy After Stroke: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03020576).
- Robotic Arm Assisted Total Knee Arthroplasty: Complete Statistical AnalysisIndependent statistical analysis of Robotic Arm Assisted Total Knee Arthroplasty: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02058069).
- Robotic Bronchoscopy for Peripheral Pulmonary Lesions: Complete Statistical AnalysisIndependent statistical analysis of Robotic Bronchoscopy for Peripheral Pulmonary Lesions: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03727425).
- Robotic Gait Rehabilitation in Parkinson’s Disease: Complete Statistical AnalysisIndependent statistical analysis of Robotic Gait Rehabilitation in Parkinson's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05218187).
- Robotic Hand Orthosis Providing Grasp Assistance for Patients With Brachial Plexus Injuries: Complete Statistical AnalysisIndependent statistical analysis of Robotic Hand Orthosis Providing Grasp Assistance for Patients With Brachial Plexus Injuries: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Robotic Pedaling Therapy for Targeted Neural Plasticity: Complete Statistical AnalysisIndependent statistical analysis of Robotic Pedaling Therapy for Targeted Neural Plasticity: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03300258).
- Robotic Single Port Donor Nephrectomy: Complete Statistical AnalysisIndependent statistical analysis of Robotic Single Port Donor Nephrectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01925677).
- Robotic Walking Device to Improve Mobility in Parkinson’s Disease: Complete Statistical AnalysisIndependent statistical analysis of Robotic Walking Device to Improve Mobility in Parkinson's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03751371).
- Robotic-assisted Therapy to Improve Manual Dexterity in Children With Cerebral Palsy: Complete Statistical AnalysisIndependent statistical analysis of Robotic-assisted Therapy to Improve Manual Dexterity in Children With Cerebral Palsy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Robotics For Rehabilitation Therapy: Functional Versus Individual Joint Training: Complete Statistical AnalysisIndependent statistical analysis of Robotics For Rehabilitation Therapy: Functional Versus Individual Joint Training: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01050231).